Table 4 Summary of Seliciclib pharmacokinetics during course 1

From: A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

 

Dose

Cmax (ng ml−1)

T max (min)

t 1/2 (min)

AUClast (min ng ml−1)

AUCinf (min ng ml−1)

Day 1

100 mg (n=3)

Mean

248

112

267

112236

115384

  

%CV

91

101

55

58

56

  

Median

134

61

278

82403

90289

 

200 mg (n=6)

Mean

179

279

176

165949

181877

  

%CV

123

95

42

62

59

  

Median

80

167

149

185025

230597

 

800 mg (n=12)

Mean

3197

177

219

3163604

3177921

  

%CV

42

68

21

43

43

  

Median

3161

120

232

3441798

3452569

Day 7

100 mg (n=3)

Mean

162

190

268

171555

173422

  

%CV

15

46

24

36

35

  

Median

152

240

234

181815

182620

 

200 mg (n=6)

Mean

310

62

781

175903

255297

  

%CV

43

71

173

59

89

  

Median

303

60

228

184620

208748

 

800 mg (n=8)

Mean

2774

99

230

1590950

1598426

  

%CV

71

26

43

69

69

  

Median

2636

107

209

1275901

1278974